These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 10632330)
1. A phase I study of recombinant interferon-beta in patients with advanced malignant disease. Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. Salmon P; Le Cotonnec JY; Galazka A; Abdul-Ahad A; Darragh A J Interferon Cytokine Res; 1996 Oct; 16(10):759-64. PubMed ID: 8910759 [TBL] [Abstract][Full Text] [Related]
5. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion. Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942 [TBL] [Abstract][Full Text] [Related]
6. Phase I study of recombinant beta ser 17 interferon in the treatment of cancer. Sarna G; Pertcheck M; Figlin R; Ardalan B Cancer Treat Rep; 1986 Dec; 70(12):1365-72. PubMed ID: 3791249 [TBL] [Abstract][Full Text] [Related]
7. A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. Hu X; Miller L; Richman S; Hitchman S; Glick G; Liu S; Zhu Y; Crossman M; Nestorov I; Gronke RS; Baker DP; Rogge M; Subramanyam M; Davar G J Clin Pharmacol; 2012 Jun; 52(6):798-808. PubMed ID: 21680782 [TBL] [Abstract][Full Text] [Related]
8. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine. Goldstein D; Sielaff KM; Storer BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC J Natl Cancer Inst; 1989 Jul; 81(14):1061-8. PubMed ID: 2472488 [TBL] [Abstract][Full Text] [Related]
9. Phase I/II trial of interferon-beta-serine in patients with renal cell carcinoma: immunological and biological effects. Rinehart JJ; Young D; Laforge J; Colborn D; Neidhart JA Cancer Res; 1987 May; 47(9):2481-5. PubMed ID: 3567933 [TBL] [Abstract][Full Text] [Related]
10. Phase I trial of combinations of recombinant interferons beta(ser) and gamma in patients with advanced malignancy. Schiller JH; Storer B; Willson JK; Borden EC Cancer Treat Rep; 1987 Oct; 71(10):945-52. PubMed ID: 3115570 [TBL] [Abstract][Full Text] [Related]
11. Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma. Kinney P; Triozzi P; Young D; Drago J; Behrens B; Wise H; Rinehart JJ J Clin Oncol; 1990 May; 8(5):881-5. PubMed ID: 2332772 [TBL] [Abstract][Full Text] [Related]
12. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. Motzer RJ; Rakhit A; Ginsberg M; Rittweger K; Vuky J; Yu R; Fettner S; Hooftman L J Clin Oncol; 2001 Mar; 19(5):1312-9. PubMed ID: 11230473 [TBL] [Abstract][Full Text] [Related]
13. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991. Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985 [TBL] [Abstract][Full Text] [Related]
14. Clinical and biological effects of recombinant interferon-beta administered intravenously daily in phase I trial. Borden EC; Hawkins MJ; Sielaff KM; Storer BM; Schiesel JD; Smalley RV J Interferon Res; 1988 Jun; 8(3):357-66. PubMed ID: 3045221 [TBL] [Abstract][Full Text] [Related]
15. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha. Greenblatt MS; Mangalik A; Ferguson J; Elias L Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023 [TBL] [Abstract][Full Text] [Related]
16. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699 [TBL] [Abstract][Full Text] [Related]
17. Biological and clinical effects of interferon-beta ser at two doses. Borden EC; Rinehart JJ; Storer BE; Trump DL; Paulnock DM; Teitelbaum AP J Interferon Res; 1990 Dec; 10(6):559-70. PubMed ID: 2086672 [TBL] [Abstract][Full Text] [Related]
18. Phase I clinical and pharmacological study of merbarone. Dimaggio JJ; Warrell RP; Muindi J; Stevens YW; Lee SJ; Lowenthal DA; Haines I; Walsh TD; Baltzer L; Yaldaei S Cancer Res; 1990 Feb; 50(4):1151-5. PubMed ID: 2297763 [TBL] [Abstract][Full Text] [Related]
19. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon. Krigel RL; Padavic-Shaller KA; Rudolph AR; Litwin S; Konrad M; Bradley EC; Comis RL Cancer Res; 1988 Jul; 48(13):3875-81. PubMed ID: 3132324 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys. Mager DE; Neuteboom B; Jusko WJ Pharm Res; 2005 Jan; 22(1):58-61. PubMed ID: 15771230 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]